Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.57 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.34 |
| ▸ | GABRP | O00591 | 3/20 | 0.33 |
| ▸ | GABRD | O14764 | 3/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.33 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.33 |
| ▸ | GABRE | P78334 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25409398 | 1.00 | SLC7A5 (0.57) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| SCHEMBL24425369 | 1.00 | SLC7A5 (0.57) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| SCHEMBL1517244 | 1.00 | SLC7A5 (0.57) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| SCHEMBL5322735 | 0.84 | SLC7A5 (0.52) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| SCHEMBL5296973 | 0.84 | SLC7A5 (0.52) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| SCHEMBL28906024 | 0.84 | SLC7A5 (0.52) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| SCHEMBL83870 | 0.82 | SLC7A5 (0.63) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| SCHEMBL2266575 | 0.82 | SLC7A5 (0.63) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| SCHEMBL9135178 | 0.82 | SLC7A5 (0.63) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| SCHEMBL4330500 | 0.82 | SLC7A5 (0.63) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021041397-A9 | COMPOSITIONS AND METHODS FOR IDENTIFYING GENE CLUSTERS | THE ROCKEFELLER UNIVERSITY (US) | 2021-04-01 | — | — | WO | claimed |
| WO-2021041397-A2 | COMPOSITIONS AND METHODS FOR IDENTIFYING GENE CLUSTERS | THE ROCKEFELLER UNIVERSITY (US) | 2021-03-04 | — | — | WO | claimed |
| US-20230234917-A1 | ASPARAGINE DERIVATIVES AND METHODS OF USING SAME | SENDA BIOSCIENCES INC (US) | 2023-07-27 | — | — | US | disclosed |
| WO-2021041397-A9 | COMPOSITIONS AND METHODS FOR IDENTIFYING GENE CLUSTERS | THE ROCKEFELLER UNIVERSITY (US) | 2021-04-01 | — | — | WO | disclosed |
| WO-2021041397-A2 | COMPOSITIONS AND METHODS FOR IDENTIFYING GENE CLUSTERS | THE ROCKEFELLER UNIVERSITY (US) | 2021-03-04 | — | — | WO | disclosed |
| US-9603943-B2 | Polyesteramide platform for site specific drug delivery | ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9603943-B2 | Polyesteramide platform for site specific drug delivery | ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20150290336-A1 | POLYESTERAMIDE PLATFORM FOR SITE SPECIFIC DRUG DELIVERY | ABBOTT CARDIOVASCULAR SYSTEMS (US) | 2015-10-15 | — | — | US | disclosed |
| US-9095619-B2 | Polyesteramide platform for site specific drug delivery | ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20150010491-A1 | POLYESTERAMIDE PLATFORM FOR SITE SPECIFIC DRUG DELIVERY | ABBOTT CARDIOVASCULAR SYSTEMS (US) | 2015-01-08 | — | — | US | disclosed |
| US-8865148-B2 | Polyesteramide platform for site specific drug delivery | ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-7778779-B2 | Method of identifying a chemical entity which is a hydroxylase modulator | ISIS INNOVATION LIMITED (GB) | 2010-08-17 | — | — | US | disclosed |
| EP-2156830-A1 | Modulators of asparaginyl hydoxylase activity of FIH | ISIS INNOVATION LIMITED (GB) | 2010-02-24 | — | — | EP | disclosed |
| EP-1554394-B1 | Screening methods using a structural model of FIH | ISIS INNOVATION (GB) | 2009-12-16 | — | — | EP | disclosed |
| US-20070258899-A1 | Diagnostic and therapeutic agents | KARYON-CTT LTD (FI) | 2007-11-08 | — | — | US | disclosed |
| US-20070243256-A1 | Polyesteramide platform for site specific drug delivery | ABBOTT CARDIOVASCULAR SYSTEMS INC. | 2007-10-18 | — | — | US | disclosed |
| US-20070048728-A1 | Hydroxylases and modulators thereof | ISIS INNOVATION LIMITED (GB) | 2007-03-01 | — | — | US | disclosed |
| EP-1554394-A2 | ASPARAGINYL HYDROXYLASES AND MODULATORS THEREOF | ISIS INNOVATION LIMITED (GB) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004035812-A2 | ASPARAGINYL HYDROXYLASES AND MODULATORS THEREOF | ISIS INNOVATION LIMITED (GB) | 2004-04-29 | — | — | WO | disclosed |
| US-6031156-A | NUCLEOTIDE SEQUENCES; FOR TRANSGENIC PLANTS WITH DARKNESS AND ORGAN SPECIFIC GENE EXPRESSION | NEW YORK UNIVERSITY (US) | 2000-02-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070243256-A1 | Polyesteramide platform for site specific drug delivery | CES2, KIT, NAAA | SLC7A5 2497/4885SLC1A3 2148/4885SLC1A2 1207/4885 |
| US-20150010491-A1 | POLYESTERAMIDE PLATFORM FOR SITE SPECIFIC DRUG DELIVERY | CES2, KIT, NAAA | SLC7A5 2497/4885SLC1A3 2148/4885SLC1A2 1207/4885 |
| US-20070048728-A1 | Hydroxylases and modulators thereof | EGLN3, HIF1AN, EGLN2 | SLC7A5 3185/4885SLC1A3 3460/4885SLC1A2 3800/4885 |
| US-20230234917-A1 | ASPARAGINE DERIVATIVES AND METHODS OF USING SAME | ASNS, SI, NARS1 | SLC7A5 86/4885SLC1A3 367/4885SLC1A2 449/4885 |
| US-20150290336-A1 | POLYESTERAMIDE PLATFORM FOR SITE SPECIFIC DRUG DELIVERY | CES2, KIT, NAAA | SLC7A5 2497/4885SLC1A3 2148/4885SLC1A2 1207/4885 |
| US-20070258899-A1 | Diagnostic and therapeutic agents | YBX1, MLX, TPX2 | SLC7A5 3712/4885SLC1A3 4472/4885SLC1A2 4787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.